A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.
What Are The Drugs Involved
The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.
The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.
These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.
What Could This Mean For Bowel Cancer Treatment In The Future
The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.
All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.
Credit: FDA
The US Food and Drug Administration (FDA) has announced a recall of organic frozen blueberries sold at Publix stores across eight US states after they were linked to a potential outbreak of E. coli infections.
GreenWise Organic IQF Blueberries were first recalled by Frutas y Hortalizas del Sur S.A. of San Carlos, Chile, which supplied the product to grocery chain Publix. Publix then recalled the frozen blueberries from its stores on July 3, 2026, according to a company statement.
According to FDA, the outbreak has resulted in 12 confirmed cases of E. coli-related gastrointestinal illness, including four hospitalizations. The FDA also said it has received reports of illness after consumers ate the frozen blueberries.
While many strains of E. coli are harmless, the bacteria involved in this recall is Shiga toxin-producing E. coli (STEC).
"E. coli O145 is a Shiga toxin-producing E. coli (STEC) that can cause illness characterised by severe stomach cramps, diarrhoea (which may be bloody), and vomiting," the FDA said.
The agency added that although most healthy people recover within a week, some infections can lead to hemolytic uremic syndrome (HUS), a serious complication that can cause kidney damage, particularly in young children, older adults, and people with weakened immune systems.
Also read: Why Fentanyl Addiction Treatments Are Losing Effectiveness, Study Finds
The recalled blueberries were distributed to Publix stores in:
The FDA advises consumers to check their freezers for the following product:
Consumers who have the affected product should not eat it. Frutas y Hortalizas del Sur S.A. said it is working closely with regulatory authorities and customers. The company has instructed all customers who received the affected lot to immediately isolate the product, stop distributing it, and notify any downstream customers.
Escherichia coli (E. coli) is a group of bacteria that normally lives in the intestines of humans and animals. Most strains are harmless and help with digestion. However, certain strains produce toxins that can cause serious illness when ingested through contaminated food or water.
An E. coli infection most commonly affects the digestive system, causing:
Some infections, particularly those caused by Shiga toxin-producing E. coli, can lead to hemolytic uremic syndrome (HUS), a potentially life-threatening condition that damages the kidneys.
You can reduce your risk of E. coli infection by:
Credit: AI
The single overnight sleep study, usually conducted to diagnose obstructive sleep apnea (OSA) may not be accurate enough, according to a recent study. Sleep patterns change significantly from one night to the next, meaning current one-night testing could underdiagnose or overestimate the condition in some patients.
The study, published in the journal npj Digital Medicine, challenges the long-standing practice of relying on a single overnight sleep study, also known as polysomnography, to diagnose OSA.
Obstructive sleep apnea is a common sleep disorder in which breathing repeatedly stops and starts during sleep due to blockage of the upper airway. If left untreated, it has been linked to serious health problems, including high blood pressure, cardiovascular disease, type 2 diabetes, stroke, and reduced quality of life.
To investigate whether a single sleep study accurately reflects a person's condition, researchers studied about 100 adults for suspected sleep apnea.
Participants underwent standard overnight polysomnography, a gold-standard diagnostic test. Simultaneously, they also had their sleep monitored repeatedly over several weeks in their home environment.
The researchers then compared the results from the one-night test with the average findings collected across multiple nights.
The analysis revealed significant night-to-night variation in sleep apnea severity. In many cases, the severity measured during one laboratory night did not match the average severity recorded over multiple nights.
As a result, some patients could get classified into the wrong severity category due to the one-night test, particularly those whose sleep apnea naturally fluctuates or whose sleep is easily affected by the unfamiliar environment.
Lead author Dr Bastien Lechat, a sleep expert at FHMRI Sleep Health, said, “Our findings show that sleep apnea can vary considerably from one night to the next, so if you only measure it once, you may not capture the true severity of the condition. In some participants, we saw clear differences between the single-night result and the average across multiple nights, which suggests current diagnostic approaches may under- or overestimate disease severity in some individuals.”
The researchers also found that patients whose classifications changed between the types of tests often experienced poorer sleep during laboratory testing. This indicated that an unfamiliar sleep environment may alter sleep quality and influence results.
Senior author Professor Sutapa Mukherjee, Professor of Respiratory and Sleep Medicine at Flinders University and Senior Consultant at Southern Adelaide Local Health Network (SALHN), said, “Our findings show that sleep apnea is a dynamic disorder, and by capturing how it changes over time, we can build a much more accurate and clinically meaningful picture of a patient's condition.”
The researchers also believe that monitoring sleep on multiple nights can help doctors assess a patient's future health risks and course of treatment in a better way.
While further research is needed before multi-night monitoring becomes routine clinical practice, the authors believe the study marks an important step toward modernizing sleep apnea diagnosis.
Credit: AI
Doctors and health experts across the United States, the United Kingdom and Australia are warning parents about a dangerous social media trend involving gel-filled "squishy" sensory toys, including the popular NeeDoh Nice Cube.
This trend has children microwaving the toys after watching viral online videos that claim it makes them softer. In many cases, the toys exploded, spraying scalding gel that caused severe burns, permanent scarring, and hospitalization in some cases.
The viral challenge got children to microwave, heat or even freeze sensory toys before squeezing them.
The thick gel inside these toys can rapidly build pressure when heated. When the toy bursts, it ejects extremely hot, sticky gel that clings to the skin, making burns deeper and more difficult to treat.
The danger is particularly high as the skin of children is thinner. Additionally, they often hold the toy close to their faces.
Several children around the world have suffered serious injuries due to the trend. One of the most widely reported cases was 9-year-old Caleb Chabolla from Illinois, who microwaved a NeeDoh Nice Cube after believing it would become softer.
As he removed it from the microwave, the toy exploded, leaving him with second-degree burns to his face and hands. He was taken to a specialized burn center.
In Australia, 10-year-old Violet Zerbst suffered severe facial burns after microwaving the toy. When she squeezed it, boiling gel splashed across her face. Her father shared the traumatic experience to warn other parents.
Another recent case involved 7-year-old Livi Barnard in the UK, whose mother says a NeeDoh toy leaked hot liquid onto her hands, causing painful burns and blisters that required repeated hospital dressing changes.
In one case, the toy exploded without being microwaved. In West Virginia, a teenager was burned after a squishy toy that had been left inside a hot car exploded, releasing hot sticky material onto her legs.
Doctors at the Royal Hospital for Children in Glasgow have seen multiple children with similar burn injuries over recent months, with some requiring skin grafts and long-term care.
Burn specialists say that these injuries are far more serious than they seem. The hot gel sticks to the skin, continuing to transfer heat for a longer time even after the initial explosion.
In severe cases, while children have required skin grafts, some have been placed in medically induced comas to protect their airways after extensive facial burns.
Medical experts are urging parents to:
The manufacturer of NeeDoh, Schylling, has already put warnings on product packaging stating that the toys should never be heated, microwaved, or frozen.
© 2024 Bennett, Coleman & Company Limited